TP53 and acute myeloid leukemia: Similar results came from a phase 1b trial of frontline magrolimab +AZA in patients with TP53-mutated AML: the ORR was 48% (CR 33.3% and CRi 8.3%), 30- and 60 days mortality were 8.3% and 18.1%, respectively, and the median OS was 10.8 months.